iCo Therapeutics Inc., a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat sight and life threatening diseases. Its in-licensed product candidates include iCo-008, a human monoclonal antibody, which is in Phase II clinical trial to treat sight threatening ocular allergies and various systemic disease indications; and Oral AmpB Delivery System that is in pre-clinical stage used for the treatment of systemic fungal infections. The company was founded in 2005 and is headquartered in Vancouver, Canada.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+1-604-6029414
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/5/2020 (Estimated)
OptionableNot Optionable
iCo Therapeutics (CVE:ICO) Frequently Asked Questions
What is iCo Therapeutics' stock symbol?
iCo Therapeutics trades on the Canadian Venture Exchange (CVE) under the ticker symbol "ICO."
When is iCo Therapeutics' next earnings date?
Has iCo Therapeutics been receiving favorable news coverage?
News articles about ICO stock have trended positive recently, according to InfoTrie. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. iCo Therapeutics earned a coverage optimism score of 3.0 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for iCo Therapeutics.
Who are some of iCo Therapeutics' key competitors?
Some companies that are related to iCo Therapeutics include Covalon Technologies (COV), OptiBiotix Health (OPTI), AquaBounty Technologies (AQB), Immunoprecise Antibodies (IPA), Actinium Pharmaceuticals (ATNM), Actinium Pharmaceuticals (ATNM), Nuformix (NFX), Medicure (MPH), Actinogen Medical (ACW), Ixico (IXI), Bionomics (BNO), Kazia Therapeutics (KZA), Rezolute (RZLT), Biocardia (BCDA) and Scancell (SCLP).
What other stocks do shareholders of iCo Therapeutics own?
Who are iCo Therapeutics' key executives?
iCo Therapeutics' management team includes the folowing people:
- Mr. Andrew J. Rae M.B.A., BSc, MBA, Co-Founder, CEO, Pres & Director (Age 52)
- Mr. Michael Liggett CPA, CA, Bsc. Pharm., CFO, Corp. Sec. & Director (Age 59)
- Dr. Peter Hnik M.D., MHSc, Chief Medical Officer (Age 63)
How do I buy shares of iCo Therapeutics?
Shares of ICO and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is iCo Therapeutics' stock price today?
One share of ICO stock can currently be purchased for approximately C$0.08.
How big of a company is iCo Therapeutics?
What is iCo Therapeutics' official website?
How can I contact iCo Therapeutics?
iCo Therapeutics' mailing address is 760-777 Hornby St, VANCOUVER, BC V6Z 1S4, Canada. The company can be reached via phone at +1-604-6029414.
MarketBeat Community Rating for iCo Therapeutics (CVE ICO)
MarketBeat's community ratings are surveys of what our community members think about iCo Therapeutics and other stocks. Vote "Outperform" if you believe ICO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICO will underperform the S&P 500 over the long term. You may vote once every thirty days.
